drugset
drugset / Trial / NCT00002952

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

NCT00002952 ↗

Phase 1/2 Completed 20 enrolled University of Chicago National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin-12 may kill more melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy plus interleukin-12 in treating patients who have metastatic melanoma.

Timeline

Start
1997-01
Primary completion
2002-08
Completion
2002-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MART-1 antigen Vaccine — Subcutaneous
Subject MELANOMA-ASSOCIATED ANTIGEN 3 Protein / enzyme biologic — Subcutaneous
Subject interleukin-12 Protein / enzyme biologic 4 ug Subcutaneous

Indications

cutaneous melanoma